What is Deca?
Deca (Nandrolone Decanoate) is one of the oldest and best-known anabolics - a 19-nor steroid with a long decanoate ester. It builds slowly and comparatively mildly and is known for the reputation of making joints feel "smoother". Clinically it was used for muscle wasting, anemia and osteoporosis.
This information is for research and educational purposes only. No medical advice.
Comparison
Nandrolone with short and long esters
The same compound at the same receptor with esters of different length, as stated in the TPD lexicon. Tap a card to open its entry.
In a direct comparison the level with the short phenylpropionate ester peaked earlier and higher than with decanoate. 9
How it works
Nandrolone activates the androgen receptor, aromatizes only weakly (less estrogen than testosterone), but - like all 19-nor compounds - has progesterone activity. That is the reason for the prolactin-related nickname "deca dick" (libido/erection issues) when prolactin is not controlled.
Where it acts
Where nandrolone decanoate acted in trials
Tap a point or a card. All effects observed in human trials.
- Skeletal muscle
Lean mass rose, on average 1.59 kg more than on placebo7
Observed in trials - Bone
Bone density rose, fewer new vertebral fractures in osteoporosis6
Observed in trials - Blood
Haemoglobin rose by 14.3% over 2 years6
Observed in trials - Liver
Raised liver enzymes in 88% in a 2-year trial10
Observed in trials - Skin
Acne in 59% in the same trial10
Observed in trials - Testes and hormone axis
Own testosterone suppressed, longest after a small injection into the glute9
Observed in trials
Targets in the ChEMBL database16
Compound CHEMBL1200946: one recorded mechanism, agonist with direct binding to the human receptor.
- Gene
- AR
- UniProt
- P10275
- ChEMBL
- CHEMBL1871
- Action
- Agonist, direct binding
Use and dosing
Dosing
Dosing, titration and syringe
Loading the dosing information …
- Getting started and stepping up, drawn as a staircase
- Units on the U-100 syringe for every step
- How long one vial lasts
What the research shows
Nandrolone decanoate has an unusually good clinical data base compared to other anabolics. The Johansen study (JAMA, 1999) showed a significant gain in fat-free mass on nandrolone vs placebo in dialysis patients. The AAS pharmacology is summarized in Kicman (2008).
Study results
What the trials measured
Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.
Gain in lean body mass14352
Change in kg from baseline, randomised trials
Where there is only one bar the abstract gives no placebo value, according to the trials the gain there was clearly smaller. Bodybuilders: from 59.54 to 63.06 kg, rounded. The meta-analysis of 20 trials found 1.59 kg more than placebo.
Older women with osteoporosis6
65 women over 70, two years, all with calcium
The increases are given against baseline. Compared with placebo, bone density at the femoral neck and trochanter and haemoglobin were significantly higher. The meta-analysis saw a clear effect only for the total hip.
Telomeres and blood formation10
Share of evaluable people, one group over 2 years
Rare inherited disorders with too short telomeres and impaired blood formation, 17 people, no placebo. Two people died of lung failure during the trial.
Research status
Where the research stands
Trials on the registry that explicitly name nandrolone decanoate. As of 26 Oct 2026. 15
- Preclinical Binding to the androgen receptor in muscle and prostate (rat, rabbit)
- Phase 1 no registered trial
- Phase 2 3 trials, 2 completed
- Phase 3 no registered trial
- Approval since 1983
Show all 6 trials on a timelineHide timeline
NCT02055456 · 20 participants, started Feb 2014, primary endpoint reached Feb 2017.
Registry entry ↗ · Results: Clé et al., Haematologica, 2023
HIP-SAP · NCT03545347 · 29 participants, started Sept 2018, primary endpoint reached May 2020.
Registry entry ↗ · Results: Hulsbæk et al., BMC Geriatrics, 2021
SARKOPENIA · NCT05978206 · 168 participants (planned), started Aug 2023, primary endpoint planned Dec 2026.
NCT00250536 · 80 participants, started Mar 2000, primary endpoint reached Oct 2004.
Registry entry ↗ · Results not yet in PubMed
Le-Na · NCT02376309 · 30 participants, started Aug 2015, primary endpoint reached Aug 2016. Tests several agents.
Registry entry ↗ · Results not yet in PubMed
NCT03263520 · 60 participants, started Feb 2016, primary endpoint reached Aug 2017. Tests several agents.
Registry entry ↗ · Results not yet in PubMed
Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026.
Side effects
- Prolactin: "deca dick" - libido/erection issues, cabergoline as countermeasure.
- HPTA suppression: strong and long-acting - longer PCT needed.
- Estrogen: weak aromatization, an AI may still be needed.
- Water retention, blood pressure.
Tolerability
Frequency in the 2-year trial
Out of 100 participants, how many had the event over 2 years. One group of 17 people, no placebo.
No event of grade 4 or higher. In a small trial after hip fracture there were 10 adverse reactions on nandrolone and 8 on placebo.1011
Storage
Store the oil solution at room temperature, protected from light - no fridge needed. Out of reach of children.